Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 773 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiovascular Disease Prevention Clear all
Completed Phase 3 Interventional Results available

A Different Approach to Preventing Thrombosis

NCT02774265
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Diabetes Prevention Program

NCT00004992
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Glucose Intolerance
Interventions
Intensive lifestyle, Metformin, Placebo
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years and older
Enrollment
3,234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2001
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 14, 2026, 1:21 PM EDT
Not listed No phase listed Observational

SCD-HeFT 10 Year Follow-up

NCT01058837
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Congestive Heart Failure, Ischemic and Non-ischemic Cardiomyopathy, Sudden Cardiac Death Primary Prevention
Interventions
Not listed
Lead sponsor
Seattle Institute for Cardiac Research
Other
Eligibility
18 Years to 90 Years
Enrollment
1,855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

NCT00501059
View directory record Official record
Conditions
Moderate Risk of CVD
Interventions
Aspirin (Acetylsalicylic acid, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
55 Years and older
Enrollment
12,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
73
States / cities
Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 14, 2026, 1:21 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT

NCT07498517
View directory record Official record
Conditions
Thrombosis
Interventions
Placebo, Gruticibart, Ultrasound, Biopspecimen collection
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 14, 2026, 1:21 PM EDT
Completed No phase listed Observational

The Effect of Implementing a Limb Loss Prevention Program on Amputation Rates

NCT03978715
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
No intervention-retrospective study
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 14, 2026, 1:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Team Lifestyle Immersion Hypertension Control Project

NCT07201948
View directory record Official record
Conditions
Hypertension
Interventions
Lifestyle Immersion Intervention that will address Nutrition, Physical Fitness, and BP Self-Monitoring3 Elements:
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
30 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Results available

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 14, 2026, 1:21 PM EDT
Not listed Phase 4 Interventional

Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

NCT00736463
View directory record Official record
Conditions
HDL Cholesterol
Interventions
Simvastatin, Atorvastatin 80 mg
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 14, 2026, 1:21 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034
View directory record Official record
Conditions
Ischemic Stroke; Ischemic Attack, Transient
Interventions
Milvexian, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
40 Years and older
Enrollment
12,523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
127
States / cities
Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 1:21 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma

NCT01050153
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Dalteparin sodium, Dalteparin sodium/aspirin
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 14, 2026, 1:21 PM EDT
Completed No phase listed Observational

Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States

NCT07214857
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

Cardiovascular Prevention for Persons With HIV

NCT00982189
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease Risk
Interventions
Pravastatin, Lisinopril
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
40 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

Early Case Management on Recovery From a Cardiac Event in Women

NCT04693988
View directory record Official record
Conditions
Cardiac Rehabilitation
Interventions
Case Management
Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 4 Interventional Results available

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

NCT04168203
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions
Apixaban 2.5 MG, Placebo oral tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

NCT01246206
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Tacrolimus and Thymoglobulin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Phase 3 Interventional

SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis

NCT00071279
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
SR34006 (idraparinux sodium) Injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
32
States / cities
Bay Pines, Florida • Brandon, Florida • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

A Behavioral Intervention To Improve Hypertension Control In Veterans

NCT00286754
View directory record Official record
Conditions
Hypertension
Interventions
SMI, HEI, UC
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 14, 2026, 1:21 PM EDT
Recruiting Phase 2 Interventional

Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)

NCT06706258
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days, Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 14, 2026, 1:21 PM EDT
Completed Not applicable Interventional Results available

The SUCCEED Trial of Secondary Stroke Prevention

NCT01763203
View directory record Official record
Conditions
Stroke, Secondary Stroke Prevention
Interventions
Care Management+Community Health Worker, Usual Care
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Downey, California • Los Angeles, California • Sylmar, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 14, 2026, 1:21 PM EDT